Document Detail


Determination of nebulizer droplet size distribution: a method based on impactor refrigeration.
MedLine Citation:
PMID:  17536948     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Size distributions of droplets generated by nebulizers are difficult to determine because of evaporation after aerosolization. We describe a method whereby a Next Generation Pharmaceutical Impactor (NGI; MSP Corporation, Shoreview, MN) is refrigerated at 5 degrees C before connecting it to the nebulizer in order to ensure an environment inside the NGI at close to 100% relative humidity (RH). This, in turn, reduces droplet evaporation between the nebulizer and impaction. The method development was performed with a Pari LC Plus jet nebulizer operated at 2.0 bar, with the NGI set at a flow rate of 15 L/min and with salbutamol 5.0 mg/mL as the test solution. The droplet size distributions were expressed in terms of mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD). Variation in test conditions showed that the NGI should be cooled for at least 90 min, that nebulization should be started within 5 min after removal from the refrigerator, and that coating of collecting cups to prevent "bouncing" is not necessary. Variation of ambient temperature and humidity had no relevant effect on results. MMAD and GSD results showed that refrigeration of the NGI resulted in droplet size distributions that are likely to reflect those originally delivered at the mouthpiece by the nebulizer. The method was shown to be robust, accurate with recovery of test solutions exceeding 99%, reproducible, and to be suitable for use with a wide range of commercially available nebulizers.
Authors:
Elna Berg; Jan Olof Svensson; Lars Asking
Related Documents :
1595028 - Prospective evaluation of the contraction stress and nonstress tests in the management ...
21424548 - The clinical management of hyperemesis gravidarum.
15663398 - Smell perception during early pregnancy: no evidence of an adaptive mechanism.
17850938 - Nausea and vomiting in pregnancy: what advice do midwives give?
21557688 - Outcome of monochorionic twin pregnancies with abnormal umbilical artery doppler betwee...
24284028 - Pregnancy outcome following gestational exposure to tnf-alpha-inhibitors: a prospective...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine     Volume:  20     ISSN:  0894-2684     ISO Abbreviation:  J Aerosol Med     Publication Date:  2007  
Date Detail:
Created Date:  2007-05-31     Completed Date:  2007-07-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8809251     Medline TA:  J Aerosol Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  97-104     Citation Subset:  T    
Affiliation:
Analytical Development, AstraZeneca R&D, Scheelevägen 2, Lund S-221 87, Sweden. elna.berg@astrazeneca.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Albuterol / administration & dosage*
Bronchodilator Agents / administration & dosage*
Chemistry, Pharmaceutical
Equipment Design
Humans
Humidity
Nebulizers and Vaporizers / standards*
Particle Size*
Refrigeration*
Volatilization
Chemical
Reg. No./Substance:
0/Bronchodilator Agents; 18559-94-9/Albuterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aerosol probes of emphysema progression in dogs treated with all trans retinoic acid--an exploratory...
Next Document:  Educational practice for inhaled treatments in French cystic fibrosis care centers.